LearnGlossaryMarketStocksSuperinvestorsSign in

DNLI

Denali Therapeutics Inc.

Healthcare · $3.3B market cap

Verdict

We can't put a fair value on DNLI right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-1.1% a year✗
Sales growth35.1% a year✓
Free cash flow growth197.3% a year✓
Return on invested capital-36.2%✗

Follow DNLI

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds DNLI right now. In Q2 2026, 1 sold out. Who we track

Moves in Q2 2026

Sold out: Polen Capital Management

Insider activity

Since Sep 1, 2026: no open-market purchases and 4 sales worth $364K. Why purchases matter

Sales

Chin Peter Scott

Chief Medical Officer · 2026-09-04

Sold

$37K

Thornberry Nancy

director · 2026-09-02

Sold

$15K

Thornberry Nancy

director · 2026-09-02

Sold

$247K

Schuth Alexander O.

COFO and Secretary · 2026-09-01

Sold

$65K

About Denali Therapeutics Inc.

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works